A clinical trial to study the effects of three different formulations of brimonidine in patients of primary open angle glaucoma.

To compare the IOP lowering efficacy and safety of brimonidine (0.2%), brimonidine purite (0.15%) and brimonidine purite (0.1%) in patients of primary open angle glaucoma / ocular hypertension

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2013/05/003666

Enrollment

Registered

2013-05-23

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- primary open angle glaucoma

Interventions

Intervention1: Brimonidine 0.2% Brimonidine purite 0.15% Brimonidine purite 0.1%: To compare efficacy and safety of brimonidine 0.2%, brimonidine purite 0.15% and brimonidine purite 0.1% in patients

Eligibility

Inclusion criteria

Inclusion criteria: 1. Minimum age of 18 years 2. Unilateral/bilateral primary open angle glaucoma. Patients with bilateral primary open angle glaucoma were treated for both eyes but only one eye was considered as study eye. 3. IOP >21mm Hg.

Exclusion criteria

Exclusion criteria: 1. History of acute angle closure glaucoma 2. History of any intraocular surgery within 6 months prior to study. 3. History of argon laser trabeculoplasty within 6 months prior to study. 4. All patients with established diagnosis of secondary glaucoma. 5. Pregnant / lactating females. 6. Women of child bearing potential who are not using contraceptive protection. 7. Any known sensitivity to the study drugs. 8. Ocular inflammation or infection. 9. Inability to cope up with the treatment plan. 10. Have participated in any other clinical study within 3 months prior to study.

Design outcomes

Primary

Measure	Time frame
Mean Intraocular pressure reduction from baseline to 6 weeks.Timepoint: 2 weeks 4 weeks 6 weeks	—

Secondary

Measure	Time frame
side effects of three formulations of brimonidineTimepoint: 2 weeks 4 weeks 6 weeks	—

Countries

India

Contacts

Public ContactDr Anubha Bhatti

Govt. Medical College Sec 32 CHD

scorpiodoc9@gmail.com8284860644

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026